Zimmer Biomet shares slid -2.8% this afternoon. Here's what you need to know about the large-capSpecialty industrial machinery company:
-
Zimmer Biomet has logged a 12.0% 52 week change, compared to 10.0% for the S&P 500
-
ZBH has an average analyst rating of hold and is -14.68% away from its mean target price of $150.64 per share
-
Its trailing earnings per share (EPS) is $2.14, which brings its trailing Price to Earnings (P/E) ratio to 60.1. The Health Care sector's average P/E ratio is 24.45
-
The company's forward earnings per share (EPS) is $8.02 and its forward P/E ratio is 16.0
-
The company has a Price to Book (P/B) ratio of 2.17 in contrast to the Health Care sector's average P/B ratio is 4.16
-
The current ratio is currently 1.9, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
ZBH has reported YOY quarterly earnings growth of 37.0% and gross profit margins of 0.7%
-
The company's free cash flow for the last fiscal year was $1.54 Billion and the average free cash flow growth rate is -6.2%
-
Zimmer Biomet's revenues have an average growth rate of -3.4% with operating expenses growing at 4.2%. The company's current operating margins stand at 17.7%